Results 141 to 150 of about 40,704 (273)

Examining the Impact of Diet‐and‐Exercise‐Induced Weight Loss on Drug Metabolism and Gastric Emptying in Patients with Obesity

The Journal of Clinical Pharmacology, EarlyView.
Abstract Obesity significantly influences drug pharmacokinetics (PK), which challenges optimal dosing. This study examines the effects of diet‐and‐exercise‐induced weight loss on key drug‐metabolizing enzymes and gastric emptying in patients with obesity, who frequently require medications for comorbidities.
Shuhan Liu, Lu Wang, Nicole Miller, Andrea Waltje, Mohamed Abdelnabi, Hao‐Jie Zhu, Duxin Sun, Amy E. Rothberg, Manjunath P. Pai   +8 more
wiley   +1 more source

CYP2C19 and CYP2D6 genotypes in Pacific peoples [PDF]

British Journal of Clinical Pharmacology, 2016
The study of pharmacogenetic variants in populations which reside in Oceania has been focused mainly on CYP2C19 and CYP2D6. Statements about the high prevalence of CYP2C19 no function genotype in ‘Pacific Islanders’ can be found in the literature. This review article summarizes the published information about these pharmacogenes in this geographical ...
openaire   +3 more sources

Both CYP2C19 and PON1 Q192R Genotypes Influence Platelet Response to Clopidogrel by Thrombelastography in Patients with Acute Coronary Syndrome

Cardiovascular Therapeutics, 2019
Objective. The objective of this study is to explore the relationships of the effects of CYP2C19 and PON1 Q192R polymorphism on the activity of clopidogrel and the risk of high platelet responsiveness (HPR) by thrombelastography in patients with acute ...
Wenxing Peng, Xiujin Shi, Xiaoyu Xu, Yang Lin   +3 more
doaj   +1 more source

Frequency and Clinical Outcomes of CYP2C19 Genotype-Guided Escalation and De-escalation of Antiplatelet Therapy in a Real-World Clinical Setting

Genetics in Medicine, 2019
To evaluate the frequency and clinical impact of switches in antiplatelet therapy following implementation of CYP2C19 genotyping after percutaneous coronary intervention (PCI).
Jesse Martin, Alexis K. Williams, Melissa D. Klein, Vindhya B. Sriramoju, S. Madan, J. Rossi, Megan M. Clarke, Jonathan D. Cicci, L. Cavallari, K. Weck, G. Stouffer, Craig R. Lee   +11 more
semanticscholar   +1 more source

Economic burden of adverse drug reactions and potential for pharmacogenomic testing in Singaporean adults. [PDF]

, 2019
Adverse drug reactions (ADRs) contribute to hospitalization but data on its economic burden is scant. Pre-emptive pharmacogenetic (PGx) testing can potentially reduce ADRs and its associated costs.
Brunham, Liam R, Chan, Alexandre, Chan, Sze Ling, Ng, Hong Yen, Sung, Cynthia, Wee, Hwee-Lin, Winther, Michael D   +6 more
core   +1 more source

Platelet Function Testing in Patients with Acute Ischemic Stroke: An Observational Study [PDF]

, 2017
Background: The measurement of platelet reactivity in patients with stroke undergoing antiplatelet therapies is not commonly performed in clinical practice.
Bigliardi, Guido, Dell'Acqua, Maria Luisa, FERRARO, Diana, Lelli, Nicoletta, Mimmi, Stefano, NICHELLI, Paolo Frigio, Pentore, Roberta, Picchetto, Livio, Rosafio, Francesca, Trenti, Tommaso, Vandelli, Laura, Zini, Andrea   +11 more
core   +1 more source

Physiologically Based Pharmacokinetic (PBPK) Model to Predict the Magnitude of Drug–Drug Interaction Between Fezolinetant and CYP1A2 Inhibitors

The Journal of Clinical Pharmacology, EarlyView.
Abstract Fezolinetant is a non‐hormonal, selective neurokinin 3 receptor antagonist approved in multiple countries including the United States, in Europe, and in Asia for the treatment of moderate to severe vasomotor symptoms in menopausal women. Fezolinetant is primarily metabolized by CYP1A2 and was found to be a sensitive substrate for CYP1A2 ...
Mary P. Choules, Yukio Otsuka, Jace C. Nielsen, Megumi Iwai, Peter L. Bonate   +4 more
wiley   +1 more source

Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine

Journal of Personalized Medicine, 2018
Variability in response to antiplatelet therapy can be explained in part by pharmacogenomics, particularly of the CYP450 enzyme encoded by CYP2C19. Loss-of-function and gain-of-function variants help explain these interindividual differences. Individuals
Sherry‐Ann Brown, N. Pereira
semanticscholar   +1 more source

Genetic Causes of Clopidogrel Nonresponsiveness: Which Ones Really Count? [PDF]

, 2010
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/91111/1/phco.30.3.265 ...
Bates, Eric R., Dorsch, Michael P., Momary, Kathryn M.   +2 more
core   +1 more source

Concomitant Use of Etrasimod With Opioids or Antidepressants in Patients With Ulcerative Colitis—A Safety Analysis

United European Gastroenterology Journal, EarlyView.
ABSTRACT Background Etrasimod is an oral, once‐daily (q.d.), selective sphingosine 1‐phosphate (S1P)1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). Unlike the S1P receptor modulator ozanimod, etrasimod does not have a molecular structure to inhibit monoamine oxidase (MAO).
Anita Afzali, Miguel Regueiro, Andres J. Yarur, Yamile Zabana, Siew C. Ng, Sujatha Menon, Aoibhinn McDonnell, Krisztina Lazin, Michael Keating, Abhishek Bhattacharjee, Diogo Branquinho, Eustratios Bananis, Laurent Peyrin‐Biroulet   +12 more
wiley   +1 more source